A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs ITI 214 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Intra-Cellular Therapies
- 25 Jul 2018 Planned number of patients changed from 32 to 40.
- 25 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018.
- 03 May 2018 According to the Intra-Cellular Therapies media release, top-line results from this trial will be available in 2H 2018.